Lam, Lok-Ka
Chan, Thomas Sau Yan
Hwang, Yu-Yan
Mak, Lung-Yi
Seto, Wai-Kay
Kwong, Yok-Lam
Yuen, Man-Fung
Article History
Received: 8 June 2023
Accepted: 25 July 2023
First Online: 1 August 2023
Declarations
:
: LY Mak serves as advisor for Gilead Sciences and Roche Diagnostics. WK Seto received speaker’s fees from AstraZeneca and Mylan, is an advisory board member of CSL Behring, is an advisory board member and received speaker’s fees from AbbVie, and is an advisory board member, received speaker’s fees and researching funding from Gilead Sciences. MF Yuen serves as advisor/consultant for AbbVie, Assembly Biosciences, Aligos Therapeutics, Arbutus Biopharma, Bristol Myer Squibb, Clear B Therapeutics, Dicerna Pharmaceuticals, Finch Therapeutics, GlaxoSmithKline, Gilead Sciences, Immunocore, Janssen, Merck Sharp and Dohme, Hoffmann-La Roche and Springbank Pharmaceuticals, Vir Biotechnology and receives grant/research support from Assembly Biosciences, Aligos Therapeutics, Arrowhead Pharmaceuticals, Bristol Myer Squibb, Fujirebio Incorporation, Gilead Sciences, Immunocore, Merck Sharp and Dohme, Hoffmann-La Roche, Springbank Pharmaceuticals and Sysmex Corporation.
: This study described de-identified clinical data and did not involve extra clinical intervention beyond the standard of care. Ethics approval was not required.
: Written consent for publication was obtained from the patient.